BRISTOL, Tenn. — King Pharmaceuticals, Inc. (NYSE:KG) announced today that total revenues increased 8% to $500 million during the second quarter ended June 30, 2006, compared to $463 million in the second quarter of 2005. Including special items, net earnings increased to $111 million and diluted earnings per share increased to $0.46 during the second…
Oct. 16, 2001 — A popular drug used to treat high blood pressure and heart disease, and recently shown to help prevent strokes and heart attacks, also appears to reduce the risk of developing diabetes. In a large trial first reported last year, researchers found that people at high risk for developing diabetes who ta…
BRISTOL, Tenn. — King Pharmaceuticals, Inc. (NYSE:KG) announced today that the Company has positive top-line results from the Phase III clinical trial evaluating the efficacy and safety of the Company’s ALTACE([R]) (ramipril) diuretic fixed-dose combination product. The Company is continuing to evaluate the trial data and expects to present the findings in detai…
(ramipril, Wyeth-Ayerst, King Pharmaceuticals)
An angiotensin-converting enzyme inhibitor for reducing the risk of MI, stroke, and death from cardiovascular causes in people aged 55 and over who are at high risk of a major cardiovascular event because of a history of coronary artery disease, stroke, peripheral vascular disease, or diabetes accompanied by at least one other cardiovascular risk factor. This is the first ACE inhibitor approved for this ind…
Actions Expected to Include 2008 Cost Savings of $75 to $90 Million
BRISTOL, Tenn. — King Pharmaceuticals, Inc. (NYSE:KG) announced today actions it is taking to accelerate a planned strategic shift, emphasizing its focus in neuroscience and hospital/acute care to maximize its long-term growth. The Company is taking these actions, which include a workforce reduction of approximately 20% and other general and administrative expense decreases, in light of recent challenges…
Sudler & Hennessey has announced the creation of S&H Group pi, a relationship marketing unit. The group will be led by Anthony Manson, a 20year veteran of the Young & Rubicam brands group (to which S&H belongs) where he developed major marketing efforts for Colgate, GSK, Merck, Pfizer, Roche and Wyeth.
Advancis Pharmaceutical Corporation has entered into a twoyear sales and market…
BRISTOL, Tenn. — King Pharmaceuticals, Inc. (NYSE: KG) announced today that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application for an ALTACE([R]) (ramipril) tablet formulation. King expects to be in a position to launch the new formulation sometime during the fourth quarter of 2007 or the first quarter of 2008.
About King Pharmaceuticals
King, headquartered in Bristol, Tenn., is a vertically integrated branded pharmaceutical comp…
NEW YORK, NEW YORK, May 16, 2003 (CCNMatthews via COMTEX)
New Graded-Release Diltiazem Formulation Outperforms “ACE” from HOPE Trial
In one of the first head-to-head trials to compare the advantages of two blood pressure treatments administered at night, Biovail Corporation’s (NYSE, TSX: BVF) Cardizem(R) LA outperformed Altace(R), the nation’s top selling branded ACE inhibitor, on trial endpoints including reductions in early-morning and 24-h…
